Status:
COMPLETED
Identification of Image Phenotypes to Predict Recurrence After Resection of Hepatocellular Carcinoma
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Median Technologies
Conditions:
CT Scans Prior to Surgery With a Least 2 Years of Follow-up
Eligibility:
All Genders
18+ years
Brief Summary
Tumor recurrence, which occurs in 70% of patients with HCC within 5 years after hepatic resection, is a major cause of post-resection-death. This recurrence can be true recurrence (intrahepatic metast...
Detailed Description
Hepatocellular carcinoma (HCC) is among the most lethal and prevalent cancers in the human population and it is now the third leading cause of cancer deaths worldwide, with over 500,000 people affecte...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Patients who underwent surgery and have R0 resection after 2010
- Multiphase CT scans with contrast media should be performed within 2 months prior to surgical intervention
- At least 2 years of follow-up data on intrahepatic recurrence
Exclusion
- Previous HCC treatment
- Combination of other anti-cancer treatment
- Other malignancies
- Patient expressly expressing opposition to the exploitation of their data as defined by the project
- Protected adults
Key Trial Info
Start Date :
January 28 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 9 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05235490
Start Date
January 28 2021
End Date
February 9 2022
Last Update
February 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Paul Brousse Hospital
Villejuif, France, 94800